Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 11;11(10):2704.
doi: 10.3390/jcm11102704.

Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022

Affiliations
Review

Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022

Bas Dijkshoorn et al. J Clin Med. .

Abstract

The risk for developing cardiovascular diseases (CVD) in rheumatoid arthritis (RA) patients is 1.5 times higher compared to the general population. This risk is partly due to the contribution of systemic inflammation in increased atherogenesis, while an increased prevalence of "traditional" cardiovascular risk factors, such as hypertension and dyslipidemia, is also attributed to nearly 50% of the total CVD risk. Most anti-rheumatic medication partly reduces this CVD risk, primarily by reducing inflammation. The increased risk is recognized by most guidelines, which advise consequent screening and multiplying calculated risk scores by 1.5. However, screening in daily clinical practice is poorly done, and RA patients often have undiagnosed and untreated risk factors. In conclusion, even nowadays, RA patients still have an increased risk of developing CVD. Advances in anti-inflammatory treatment partly mitigate this risk, but RA patients need mandatory screening for CV risk factors to turn their CVD risk towards that of the general population.

Keywords: cardiovascular diseases; cardiovascular risk management; inflammation; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

B.D. and R.R. have no disclosures. M.N has no relevant disclosure.

References

    1. Almutairi K., Nossent J., Preen D., Keen H., Inderjeeth C. The global prevalence of rheumatoid arthritis: A meta-analysis based on a systematic review. Rheumatol. Int. 2021;41:863–877. doi: 10.1007/s00296-020-04731-0. - DOI - PubMed
    1. Hermans M.P.J., van der Velden D., Montero Cabezas J.M., Putter H., Huizinga T.W.J., Kuiper J., Toes R.E.M., Schalij M.J., Wouter Jukema J., van der Woude D. Long-term mortality in patients with ST-segment elevation myocardial infarction is associated with anti-citrullinated protein antibodies. Int. J. Cardiol. 2017;240:20–24. doi: 10.1016/j.ijcard.2017.04.046. - DOI - PubMed
    1. Ciobanu D.A., Poenariu I.S., Crînguș L.-I., Vreju F.A., Turcu-Stiolica A., Tica A.A., Padureanu V., Dumitrascu R.M., Banicioiu-Covei S., Dinescu S.C., et al. JAK/STAT pathway in pathology of rheumatoid arthritis (Review) Exp. Ther. Med. 2020;20:3498–3503. doi: 10.3892/etm.2020.8982. - DOI - PMC - PubMed
    1. Malemud C.J. The role of the JAK/STAT signal pathway in rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis. 2018;10:117–127. doi: 10.1177/1759720X18776224. - DOI - PMC - PubMed
    1. Cojocaru M., Cojocaru I.M., Silosi I., Vrabie C.D., Tanasescu R. Extra-articular Manifestations in Rheumatoid Arthritis. Maedica. 2010;5:286–291. - PMC - PubMed

LinkOut - more resources